REGN240802P1120000
- 65.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,150
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,182
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Regeneron Pharmaceuticals Analyst Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,166
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
Regeneron Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Regeneron Pharmaceuticals Analyst Ratings
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183
Regeneron Pharmaceuticals Analyst Ratings
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050
Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook